COIOSDeep risk insights through multi-disciplinary research across the globe
a view of a city at night from the top of a hill
Item new Peer-reviewed Added

New-generation drug-eluting stents judged cost-effective over bare-metal stents in Taiwan

In Taiwan, new-generation drug-eluting stents were linked to 43% lower five-year mortality after myocardial infarction, at NT$302,750 per death avoided.

This study compared new-generation drug-eluting stents with bare-metal stents after myocardial infarction, from Taiwan's national health insurance perspective. It used all 10,672 patients stented in 2018, followed to 2023, and matched 3,913 per group by propensity score. Drug-eluting stents were linked to 52%, 48% and 43% lower 1-, 2- and 5-year mortality, and NT$27,839 higher 1-year cost. The incremental cost per death avoided was NT$463,983, NT$241,299 and NT$302,750 at 1, 2 and 5 years. Against the World Health Organization threshold, the authors judged these stents cost-effective. Effectiveness was counted as deaths avoided rather than quality-adjusted life years, and the abstract states no limitations.

Why it is interesting: Drug-eluting stents are the preferred treatment for myocardial infarction, yet some national insurance systems do not reimburse them. This study prices their survival gain over five years in a whole national cohort.

Source
International Journal for Quality in Health Care, 19 November 2026
Paper
Cost-effectiveness analysis of new-generation drug-eluting stents for myocardial infarction: a nationwide population-based study
Authors
Tung YC, Chang GM
DOI
10.1093/intqhc/mzag193
Type
Peer-reviewed article
Design
Nationwide propensity-matched cohort (10,672 MI patients, 3,913 per arm, 2018-2023) with Cox and linear regression and ICER calculation
Verdict
New finding
Driver
Value in health

Other drivers in Data, models and systems